PATENT CLAIM ANALYSIS

Application Number: 15910332
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "007300"]

Abstract:
The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a β-Klotho-binding protein, an FGFR1c-binding protein, a β-Klotho-binding protein and a FGFR1c-binding protein, a C-terminal region from FGF19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.

Claim (Index 10):
The isolated mutated mature FGF1 protein of  claim 8 , wherein the point mutation at K112 is K112Q and the point mutation at K113 is K113Q.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 90.0
- Lexical Diversity: 1.64384
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14520178', '15598420', '15289447', '14176992', '15289544']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8089134454244716
- 35 USC 102 Novelty (BERT): 0.6651953902200176
- Combined Prediction Score: 0.7945416399040263
- Mean Citation Score: 490.60944000000006
- Max Citation Score: 781.3792
- Similarity Product: 605.425600270462

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test